Archives

img-01

“Action Program” for Generics in Japan

On October 15, 2007 Japan’s Ministry of Health, Labor and Welfare (MHLW) announced its “Action Program” to promote the generics market. Intended in part to increase the market share of generics to more than 30% by 2012, this Action Program will cover... Read More

img-01

Improving Japan’s Medical Markets

The U.S.-Japan Regulatory Reform and Competition Policy Initiative issued its sixth report this June. The report outlined various recommendations to facilitate economic growth and increased trade between the two countries, including plans for the medical device and pharmaceutical market. Most of the... Read More

img-01

Japan’s Changing Biotechnology Market

The biotech market in Japan is one of the largest in the world at over $15 billion. With various government incentives such as tax exemptions and annual funding, the biotech market is steadily growing. Foreign companies have also increased their presence with... Read More

img-01

Japan’s Plans to Promote Generics Market

The Ministry of Health, Labor, and Welfare (MHLW) has recently focused on the generics market, with new regulations and planned regulations for the future. On April 18, 2007, the Central Social Insurance Medical Council (Chuikyo) approved adding generic drugs to the National... Read More

img-01

Conducting Clinical Trials in Asia

With steadily increasing drug development costs and significant time spent on clinical trials, outsourcing clinical trials in Asia has rapidly become an appealing option for many firms. As developing a single drug can cost more than $200 million and take at least... Read More

img-01

Plans to Decrease Drug Lag in Japan

On October 10, 2006 the Ministry of Health, Labor and Welfare of Japan, the Pharmaceuticals and Medical Devices Agency of Japan (PMDA), and the US FDA held a conference on drug review and safety to assess current pharmaceutical regulations and trends in... Read More